Phoenix New Media Hong Kong stock | Tengsheng Boyao-B (02137) continued its rise yesterday, rising 6.98% to HK $33.70 with a turnover of HK $31.96 million as of press time.

On the news side, the company recently announced that the company has completed the first patient administration in the BRII-179 (VBI2601) 2a/2b phase clinical trial of chronic hepatitis B virus (HBV) patients. It is estimated that 290 million people worldwide suffer from chronic HBV infection, and nearly 800000 people die each year from complications such as HBV-related liver cirrhosis, liver failure and liver cancer. BRII-179 (VBI-2601) is a new candidate drug for HBV immunotherapy based on recombinant protein, which can express Pre-S1, Pre-S2 and S hepatitis B surface antigen and aims to enhance B cell and T cell immunity.